1) BL-8040 for the treatment of relapsed/refractory acute myeloid leukemia in Q2 2013. Partial results from this trial are expected in Q4 2013 and final results in the second half of 2014.
2)The company is planning to commence pivotal CE-Mark registration trial of BL-5010 for European approval in the second half of 2013. BL-5010 is being developed for the non-surgical removal of skin lesions.
3)BioLineRx said that it expects partial results from a phase 1/2 clinical trial of BL-8020 in hepatitis C virus to be reported in Q4 2013 and final results in the first half of 2014.
4) BL-7010 will be presented at the Digestive Disease Week 2013 conference, the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, to be held on May 18-21, 2013 in Orlando, Florida.
As you can see, quite a few big time catalyst for the back end of this year in Q3 and Q4. The Hep C results for BL-8020 and Leukemia results from BL-8040 will be the most important. How you play these catalyst are up to you. Personally I'm loading up now in this dip and waiting for the run up in Q3/Q4 as we get nearer to BioLine reporting results from these various trials